tradmap

CCEL Financials CRYO CELL INTERNATIONAL INC

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 0.3% per year over the past 5 years.
  • Operating margin has contracted, at 1.5% in the latest year.
  • Free cash flow has declined 8.9% per year over the past 5 years.

Financial health

  • Total debt ($8M) exceeds cash ($319031); net debt is $8M.
  • Total debt has grown faster than revenue (7.1% vs 0.3% per year).
  • Operating income covered interest expense 0.2× in the latest year, down from 5.0× 5 years ago.
  • Total debt is 5.7× EBITDA.

Shareholder returns

  • Dividends have been paid for 2 consecutive years, consuming 61.6% of free cash flow.
Revenue & net income
-$10M $11M $32M $0 2011 2013 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
-39% 19% 77% 0% 2011 2013 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Return on equity & assets (ROE / ROA)
-182% -48% 86% 0% 2011 2013 2015 2017 2019 2021 2023 2025
ROEROA
Free cash flow (CFO − capex)
-$4M $2M $8M $0 2011 2013 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $6M $13M 2011 2013 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$15M -$3M $9M $0 2011 2013 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MROEROAFCFTotal debtCash
2025 $32M -$2M 76.6% 1.5% 13.1% -3.9% $5M $8M $319031
2024 $32M $402095 75.2% 10.9% -3.0% 0.6% $4M $8M $560960
2023 $31M -$10M 73.2% -39.3% 86.3% -14.7% $2M $9M $406067
2022 $30M $3M 71.0% 13.3% -181.8% 4.3% -$4M $9M $2M
2021 $29M $2M 68.9% 13.9% 49.8% 3.4% $6M $2M $8M
2020 $31M $4M 69.0% 24.6% -136.0% 7.8% $8M $6M $10M
2019 $32M $2M 68.5% 15.9% -32.9% 5.3% $6M $9M $7M
2018 $29M -$854824 70.8% 17.8% 9.6% -2.0% $5M $13M $6M
2017 $25M $2M 73.5% 19.7% -18.5% 9.7% $6M $7M $6M
2016 -$1M 8.6% -6.8% $10M $3M
2015 $8M -163.3% 41.6% $2M $4M
2014 $553623 -5.2% 5.4% $2M $3M
2013 $27436 -0.3% 0.2% $472196 $2M $4M
2012 -$6M 70.1% -51.2% $227363 $2M $3M
2011 -$2M 85.2% -10.8% $313407 $3M $6M

Valuation over time

How the market has priced CCEL against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 77.9 155.8 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/E
Price / sales (P/S)
0.0 1.1 2.2 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/S
Dividend yield (%)
0.0 15.5 31.1 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
Dividend yield %

Frequently asked questions

Is CCEL growing its revenue and profit?

Over the past 5 years, CRYO CELL INTERNATIONAL INC's revenue has grown 0.3% per year. These are computed facts, not advice.

How much debt does CCEL have?

As of FY2025, CRYO CELL INTERNATIONAL INC reported $8M of total debt against $319031 of cash; operating income covered interest expense 0.2×.

What is CCEL's profit margin?

In FY2025, gross margin was 76.6%, operating margin 1.5%, and net margin -7.7%.

What is CCEL's P/E ratio?

As of Sep '26, CRYO CELL INTERNATIONAL INC traded at a price-to-earnings ratio of about 88.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.